[1] Ayusawa M,Sonobe T,Uemura S,et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition)[J].Pediatr Int,2005,47(2):232-234. [2] Newburger JW,Takahashi M,Gerber MA,et al.Diagnosis,treatment,and long-term management of Kawasaki disease:a statement for health professionals from the committee on rheumatic fever,endocarditis,and Kawasaki disease,council on cardiovascular disease in the young,american heart association[J].Pediatrics,2004,114(6):1708-1733. [3] 郭爱红.62例川崎病合并关节炎患儿的治疗及预后分析[J].河南医学研究,2017,26(24):4488-4489. [4] Álvarez EP,Rey F,Peña SC,et al.Has joint involment lessened in Kawasaki Disease?[J].Reumatol Clin,2017,13(3):145-149. [5] Gong GW,McCrindle BW,Ching JC,et al.Arthritis presenting during the acute phase of Kawasaki disease[J].J Pediatr,2006,148(6):800-805. [6] Lee KY,Oh JH,Han JW,et al.Arthritis in Kawasaki disease after responding to intravenous immunoglobulin treatment[J].Eur J Pediatr,2005,164(7):451-452. [7] 郑代明,孟晓慧,高志伟,等.川崎病患儿多器官损害及其冠状动脉瘤的发生[J].医学研究杂志,2008,37(1):84-86. [8] 郑代明,孟晓慧,郭义威,等.川崎病患儿关节受累的临床特点[J].中华实用儿科临床杂志,2007,22(23):1831. [9] 唐佳文.川崎病少见表现对其诊断的临床意义[J].中外医学研究,2013,11(26):123-124. [10] 兰由玉,王友强.川崎病少见表现对其诊断的临床意义[J].泸州医学院学报,2013,36(1):71-73. [11] 许喜闻.川崎病合并关节炎患儿临床分析[J].江西医药,2014,49(10):1061-1062. [12] 王华彬,王萍,罗开源,等.丙种球蛋白非敏感型川崎病并发关节痛1例[J].赣南医学院学报,2016,36(3):432-433. [13] 曹阳.儿童川崎病与关节炎关系的研究进展[J].国际儿科学杂志,2016,43(8):611-613. [14] Cimaz R,Sundel R.Atypical and incomplete Kawasaki disease[J].Best Pract Res Clin Rheumatol,2009,23(5):689-697. [15] 张永兰,杜忠东,赵地,等.2000-2004年北京川崎病住院患儿流行病学调查[J].实用儿科临床杂志,2007,22(1):12-15. [16] 张晓梅,张宇,张圳,等.吉林省1999-2008年小儿川崎病流行病学调查[J].实用儿科临床杂志,2010,25(1):28-30. [17] Kibata T,Suzuki Y,Hasegawa S,et al.Coronary artery lesions and the increasing incidence of Kawasaki disease resistant to initial immunoglobulin[J].Int J Cardiol,2016,214:209-215. [18] Sang ML,Lee JB,Go YB,et al.Prediction of resistance to standard intravenous immunoglobulin therapy in Kawasaki disease[J].Kor Circ J,2014,44(6):415-422. [19] 徐琨,段炤,韩菲,等.丙种球蛋白无反应性川崎病相关因素探讨[J].江西医药,2013,48(9):768-770. [20] Berdej-Szczot E,Małecka-Tendera E,Gawlik T,et al.Risk factors of immunoglobulin resistance and coronary complications in children with Kawasaki disease[J].Kardiol Pol,2017,75(3):261-266. [21] 朴金花,金莲花,孙景辉,等.大剂量静脉注射丙种球蛋白无反应性川崎病的临床分析[J].临床儿科杂志,2009,27(5):480-483. [22] 梁雪,金莲花,张胜,等.丙种球蛋白无反应性川崎病的临床特点及危险因素分析[J].中国实验诊断学,2017,21(4):679-681. [23] 王叶,王旭,钟英杰,等.小儿不完全性川崎病的诊断与临床观察[J].中国实验诊断学,2016,20(6):1015-1018. [24] Downie ML,Manlhiot C,Latino GA,et al.Variability in response to intravenous immunoglobulin in the treatment of Kawasaki disease[J].J Pediatr,2016,179:124-130. [25] Uehara R,Belay ED,Maddox RA,et al.Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan[J].Pediatr Infect Dis J,2008,27(2):155-160. [26] Jin-Young B,Song MS.Meta-analysis of factors predicting resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease[J].Korean J Pediatr,2016,59(2):80-90. |